ZSCAN2

Summary

ZSCAN2 (zinc finger and SCAN domain containing 2, HGNC:20994) is a protein-coding gene on chromosome 15q25.2, encoding Zinc finger and SCAN domain-containing protein 2 (Q7Z7L9). May be involved in transcriptional regulation during the post-meiotic stages of spermatogenesis.

The protein encoded by this gene contains several copies of zinc finger motif, which is commonly found in transcriptional regulatory proteins. Studies in mice show that this gene is expressed during embryonic development, and specifically in the testis in adult mice, suggesting that it may play a role in regulating genes in germ cells. Alternative splicing of this gene results in several transcript variants encoding different isoforms.

Source: NCBI Gene 54993 — RefSeq curated summary.

At a glance

• GWAS associations: 22
• Clinical variants (ClinVar): 81 total
• MANE Select transcript: NM_181877

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20994
Approved symbol	ZSCAN2
Name	zinc finger and SCAN domain containing 2
Location	15q25.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ20595, ZNF854
Ensembl gene	ENSG00000176371
Ensembl biotype	protein_coding
Entrez	54993

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 15 protein_coding, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000303310, ENST00000327179, ENST00000334141, ENST00000358472, ENST00000379358, ENST00000442073, ENST00000448803, ENST00000485222, ENST00000502939, ENST00000538076, ENST00000540894, ENST00000540936, ENST00000541040, ENST00000546148, ENST00000546275, ENST00000928202, ENST00000928203

RefSeq mRNA: 3 — MANE Select: NM_181877 NM_001007072, NM_017894, NM_181877

CCDS: CCDS10329, CCDS32315, CCDS32316

Canonical transcript exons

ENST00000546148 — 3 exons

Exon	Start	End
ENSE00001230992	84603820	84604333
ENSE00002316621	84601009	84601135
ENSE00003624338	84620602	84623716

Expression profiles

Bgee: expression breadth ubiquitous, 216 present calls, max score 88.66.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.3797 / max 52.4539, expressed in 1710 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
148131	5.5585	1702
148132	0.5951	247
148136	0.0860	33
148134	0.0679	30
148135	0.0528	31
148133	0.0195	8

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	88.66	gold quality
ganglionic eminence	UBERON:0004023	86.13	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.89	gold quality
cortical plate	UBERON:0005343	84.53	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.61	gold quality
oviduct epithelium	UBERON:0004804	83.59	gold quality
body of pancreas	UBERON:0001150	81.92	gold quality
pancreas	UBERON:0001264	80.56	gold quality
stromal cell of endometrium	CL:0002255	79.92	gold quality
apex of heart	UBERON:0002098	79.77	gold quality
upper arm skin	UBERON:0004263	79.55	gold quality
bone marrow cell	CL:0002092	79.50	gold quality
pancreatic ductal cell	CL:0002079	79.21	silver quality
ventricular zone	UBERON:0003053	79.14	gold quality
monocyte	CL:0000576	79.09	gold quality
leukocyte	CL:0000738	78.83	gold quality
islet of Langerhans	UBERON:0000006	78.35	gold quality
oocyte	CL:0000023	77.55	silver quality
thymus	UBERON:0002370	77.42	gold quality
testis	UBERON:0000473	77.20	gold quality
buccal mucosa cell	CL:0002336	77.11	gold quality
right lobe of liver	UBERON:0001114	77.01	gold quality
gastrocnemius	UBERON:0001388	76.81	gold quality
muscle of leg	UBERON:0001383	76.76	gold quality
body of stomach	UBERON:0001161	76.44	gold quality
hindlimb stylopod muscle	UBERON:0004252	76.40	gold quality
left testis	UBERON:0004533	76.20	gold quality
stomach	UBERON:0000945	75.96	gold quality
colonic epithelium	UBERON:0000397	75.86	gold quality
right testis	UBERON:0004534	75.72	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-6058	no	236.16
E-ANND-3	no	4.40

Regulation

Is transcription factor: yes

JASPAR motifs

Motif	Name	Family
MA2516.1	ZSCAN2	More than 3 adjacent zinc fingers

JASPAR matrix evidence (PMIDs): PMID:39605320

miRNA regulators (miRDB)

10 targeting ZSCAN2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-4279	99.19	66.70	2437
HSA-MIR-211-3P	98.14	66.77	1052
HSA-MIR-6893-3P	97.79	64.91	1238
HSA-MIR-4675	97.69	64.82	774
HSA-MIR-4741	97.69	64.14	883
HSA-MIR-370-3P	97.09	64.92	1221
HSA-MIR-4683	95.29	65.98	631
HSA-MIR-764	94.16	64.85	656

Literature-anchored findings (GeneRIF, showing 1)

• PMID:1937051 pertains to studies in mouse. (PMID:1937051)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zscan2	ENSMUSG00000038797
rattus_norvegicus	Zscan2	ENSRNOG00000022164

Paralogs (38): ZFX (ENSG00000005889), ZBTB11 (ENSG00000066422), ZFAT (ENSG00000066827), ZFY (ENSG00000067646), ZNF586 (ENSG00000083828), IKZF5 (ENSG00000095574), ZNF419 (ENSG00000105136), ZNF549 (ENSG00000121406), ZSCAN20 (ENSG00000121903), ZNF304 (ENSG00000131845), PRDM15 (ENSG00000141956), ZNF660 (ENSG00000144792), ZNF711 (ENSG00000147180), ZNF773 (ENSG00000152439), ZNF256 (ENSG00000152454), ZNF837 (ENSG00000152475), ZNF691 (ENSG00000164011), ZNF610 (ENSG00000167554), E4F1 (ENSG00000167967), ZNF562 (ENSG00000171466), ZNF561 (ENSG00000171469), ZNF584 (ENSG00000171574), ZIK1 (ENSG00000171649), ZNF570 (ENSG00000171827), ZNF552 (ENSG00000178935), ZNF154 (ENSG00000179909), ZNF792 (ENSG00000180884), ZNF793 (ENSG00000188227), ZNF548 (ENSG00000188785), ZNF79 (ENSG00000196152), ZNF418 (ENSG00000196724), ZNF772 (ENSG00000197128), ZNF583 (ENSG00000198440), ZNF480 (ENSG00000198464), ZNF551 (ENSG00000204519), ZNF134 (ENSG00000213762), ZNF587B (ENSG00000269343), ZNF8 (ENSG00000278129)

Protein

Protein identifiers

Zinc finger and SCAN domain-containing protein 2 — Q7Z7L9 (reviewed: Q7Z7L9)

Alternative names: Zinc finger protein 29 homolog, Zinc finger protein 854

All UniProt accessions (10): A0A0C4DFQ3, Q7Z7L9, F5GY18, F5GZ04, F5H1K4, F5H2D8, F5H3F3, F5H4P1, F5H789, F8W6Y9

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation during the post-meiotic stages of spermatogenesis.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q7Z7L9-1	1	yes
Q7Z7L9-3	3
Q7Z7L9-4	4

RefSeq proteins (3): NP_001007073, NP_060364, NP_870992* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003309	SCAN_dom	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR038269	SCAN_sf	Homologous_superfamily
IPR050329	GLI_C2H2-zinc-finger	Family

Pfam: PF00096, PF02023

UniProt features (25 total): zinc finger region 14, splice variant 4, region of interest 2, sequence conflict 2, chain 1, domain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z7L9-F1	70.22	0.17

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 90 (showing top): DARWICHE_PAPILLOMA_PROGRESSION_RISK, GOBP_MALE_GAMETE_GENERATION, SOX9_B1, IRF_Q6, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, MIKKELSEN_MCV6_LCP_WITH_H3K4ME3, MIKKELSEN_MEF_LCP_WITH_H3K4ME3, MIKKELSEN_IPS_LCP_WITH_H3K4ME3, MIKKELSEN_NPC_LCP_WITH_H3K4ME3, DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN, GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, IRF1_01, CTIP_DN.V1_DN, PKCA_DN.V1_DN

GO Biological Process (4): regulation of transcription by RNA polymerase II (GO:0006357), spermatogenesis (GO:0007283), cell differentiation (GO:0030154), positive regulation of transcription by RNA polymerase II (GO:0045944)

GO Molecular Function (6): RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), transcription cis-regulatory region binding (GO:0000976), DNA binding (GO:0003677), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	2
regulation of transcription by RNA polymerase II	2
regulation of DNA-templated transcription	1
developmental process involved in reproduction	1
male gamete generation	1
cellular developmental process	1
positive regulation of DNA-templated transcription	1
transcription cis-regulatory region binding	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
transition metal ion binding	1
transcription regulatory region nucleic acid binding	1
sequence-specific double-stranded DNA binding	1
nucleic acid binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

462 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZSCAN2	SPATA24	Q86W54	542
ZSCAN2	SCAND1	P57086	510
ZSCAN2	D6RC18	D6RC18	503
ZSCAN2	TSKU	Q8WUA8	454
ZSCAN2	TDRD3	Q9H7E2	449
ZSCAN2	FEM1B	Q9UK73	444
ZSCAN2	MAP10	Q9P2G4	437
ZSCAN2	NME8	Q8N427	433
ZSCAN2	ING5	Q8WYH8	426
ZSCAN2	ZNF174	Q15697	423
ZSCAN2	C7orf25	Q9BPX7	419
ZSCAN2	ZNF202	O95125	403
ZSCAN2	ZNF24	P17028	391
ZSCAN2	ZNF839	A8K0R7	385
ZSCAN2	TMEM169	Q96HH4	383

IntAct

6 interactions, top by confidence:

A	B	Type	Score
ZSCAN2	UQCRHL	psi-mi:“MI:0915”(physical association)	0.400
NOTCH2	ZNF320	psi-mi:“MI:0914”(association)	0.350
PNMA8A	AP3B1	psi-mi:“MI:0914”(association)	0.350
TIMM50	ZNF320	psi-mi:“MI:0914”(association)	0.350
HDAC8	SEC16A	psi-mi:“MI:0914”(association)	0.350

BioGRID (9): ZSCAN2 (Proximity Label-MS), ZSCAN2 (Affinity Capture-MS), ZSCAN2 (Affinity Capture-MS), ZSCAN2 (Affinity Capture-MS), ZSCAN2 (Affinity Capture-MS), ZSCAN2 (Affinity Capture-MS), ZSCAN2 (Affinity Capture-MS), ZSCAN2 (Affinity Capture-MS), ZSCAN2 (Affinity Capture-MS)

ESM2 similar proteins: A1YEP8, A1YEV9, A1YFW2, A1YG26, A1YG48, A1YG60, A2T6E3, A2T6V8, A2T712, A2T736, A2T7D2, A2T7F4, A2T7L7, A2T812, A6QNZ0, O14709, O15535, O43296, O43309, P10073, P17023, P17097, P49910, Q07231, Q12901, Q15776, Q16670, Q1LZ87, Q3MJ62, Q53GI3, Q571J5, Q5JNZ3, Q5RAE6, Q5RBX0, Q5RCD9, Q5RJ54, Q7Z7L9, Q86W11, Q8IZ26, Q8NF99

Diamond homologs: A1YEP8, A1YEQ3, A1YEV9, A1YFW2, A1YFW6, A1YG26, A1YG48, A1YG60, A1YGJ4, A1YGK6, A2T6E3, A2T6V8, A2T6W2, A2T712, A2T736, A2T7D2, A2T7D7, A2T7F2, A2T7F4, A2T7L7, A2T812, A6QNZ0, A6QPT6, B2KFW1, O14709, O14771, O14978, O15535, O43309, O60304, O95125, P10073, P17022, P17028, P17029, P17040, P28698, P49910, P51815, P59923

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

81 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	72
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

864 predictions. Top by Δscore:

Variant	Effect	Δscore
15:84604331:GTG:G	donor_gain	1.0000
15:84616421:G:GT	donor_gain	1.0000
15:84620592:ATT:A	acceptor_gain	1.0000
15:84620599:CAGAT:C	acceptor_loss	1.0000
15:84620600:A:AG	acceptor_gain	1.0000
15:84620600:AGAT:A	acceptor_loss	1.0000
15:84620601:G:GG	acceptor_gain	1.0000
15:84603816:TCAGC:T	acceptor_loss	0.9900
15:84603817:CAG:C	acceptor_loss	0.9900
15:84603818:A:AG	acceptor_gain	0.9900
15:84603818:AGC:A	acceptor_gain	0.9900
15:84603818:AGCG:A	acceptor_gain	0.9900
15:84603818:AGCGG:A	acceptor_gain	0.9900
15:84603819:G:GG	acceptor_gain	0.9900
15:84603819:G:GT	acceptor_loss	0.9900
15:84603819:GC:G	acceptor_gain	0.9900
15:84603819:GCG:G	acceptor_gain	0.9900
15:84603819:GCGG:G	acceptor_gain	0.9900
15:84603819:GCGGG:G	acceptor_gain	0.9900
15:84604301:TGG:T	donor_gain	0.9900
15:84604327:G:GT	donor_gain	0.9900
15:84604328:A:T	donor_gain	0.9900
15:84620592:A:AG	acceptor_gain	0.9900
15:84620593:T:G	acceptor_gain	0.9900
15:84620594:T:TA	acceptor_gain	0.9900
15:84620601:GA:G	acceptor_gain	0.9900
15:84620601:GATT:G	acceptor_gain	0.9900
15:84603821:G:A	acceptor_gain	0.9800
15:84620601:GATTT:G	acceptor_gain	0.9800
15:84601184:CCGAG:C	donor_loss	0.9700

AlphaMissense

4139 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:84621138:T:C	F315L	1.000
15:84621140:C:A	F315L	1.000
15:84621140:C:G	F315L	1.000
15:84621222:T:C	F343L	1.000
15:84621224:T:A	F343L	1.000
15:84621224:T:G	F343L	1.000
15:84621306:T:C	F371L	1.000
15:84621308:T:A	F371L	1.000
15:84621308:T:G	F371L	1.000
15:84621054:T:C	F287L	0.999
15:84621056:T:A	F287L	0.999
15:84621056:T:G	F287L	0.999
15:84621073:T:C	L293P	0.999
15:84621083:C:A	H296Q	0.999
15:84621083:C:G	H296Q	0.999
15:84621157:T:C	L321P	0.999
15:84621172:G:C	R326P	0.999
15:84621241:T:C	L349P	0.999
15:84621325:T:C	L377P	0.999
15:84621390:T:C	F399L	0.999
15:84621392:C:A	F399L	0.999
15:84621392:C:G	F399L	0.999
15:84621474:T:C	F427L	0.999
15:84621476:C:A	F427L	0.999
15:84621476:C:G	F427L	0.999
15:84621810:T:C	F539L	0.999
15:84621812:C:A	F539L	0.999
15:84621812:C:G	F539L	0.999
15:84621894:T:C	F567L	0.999
15:84621896:T:A	F567L	0.999

dbSNP variants (sampled 300 via entrez): RS1000029694 (15:84616411 C>T), RS1000033862 (15:84622220 G>A,C), RS1000074877 (15:84607882 C>T), RS1000170774 (15:84622959 G>C,T), RS1000459126 (15:84605173 A>AT), RS1000529069 (15:84612157 C>T), RS1000549252 (15:84616697 A>G,T), RS1000558610 (15:84600871 T>C), RS1000623715 (15:84611858 C>T), RS1000693681 (15:84617478 C>T), RS1000704425 (15:84623180 C>A,T), RS1000877945 (15:84600479 C>A,T), RS1000998083 (15:84606286 C>T), RS1001121005 (15:84615982 C>G), RS1001142867 (15:84605989 A>C,G)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

22 associations (top):

Study	Trait	p-value
GCST002539_78	Schizophrenia	2.000000e-11
GCST004521_253	Autism spectrum disorder or schizophrenia	6.000000e-11
GCST004562_151	Waist circumference adjusted for body mass index	2.000000e-08
GCST004562_47	Waist circumference adjusted for body mass index	6.000000e-09
GCST004563_133	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	3.000000e-08
GCST004563_200	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	8.000000e-06
GCST004563_28	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)	1.000000e-07
GCST004564_181	Waist circumference adjusted for BMI in active individuals	1.000000e-06
GCST004564_182	Waist circumference adjusted for BMI in active individuals	1.000000e-08
GCST004564_183	Waist circumference adjusted for BMI in active individuals	2.000000e-06
GCST004564_184	Waist circumference adjusted for BMI in active individuals	5.000000e-06
GCST004564_185	Waist circumference adjusted for BMI in active individuals	4.000000e-08
GCST004946_90	Schizophrenia	5.000000e-12
GCST006630_69	Diastolic blood pressure	1.000000e-10
GCST006803_69	Schizophrenia	9.000000e-10
GCST008103_25	Bipolar disorder	3.000000e-08
GCST008163_168	Height	9.000000e-08
GCST008595_97	Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)	3.000000e-10
GCST009600_133	Anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy)	5.000000e-14
GCST90011899_116	Aspartate aminotransferase levels	1.000000e-09
GCST90020028_1357	Hip circumference adjusted for BMI	5.000000e-11
GCST90020029_766	Waist circumference adjusted for body mass index	3.000000e-08

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0007789	BMI-adjusted waist circumference
EFO:0008002	physical activity measurement
EFO:0006336	diastolic blood pressure
EFO:0004337	intelligence
EFO:0004784	self reported educational attainment
EFO:0004736	aspartate aminotransferase measurement
EFO:0008039	BMI-adjusted hip circumference

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases methylation, affects methylation	2
Cisplatin	affects expression, increases expression	2
triphenyl phosphate	affects expression	1
sodium arsenite	decreases expression	1
benzo(e)pyrene	increases methylation	1
cupric oxide	increases expression	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
di-n-butylphosphoric acid	affects expression	1
bisphenol S	decreases methylation	1
Decitabine	affects expression	1
Arsenic Trioxide	affects binding, decreases reaction	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Hydrogen Peroxide	affects expression	1
Methapyrilene	increases methylation	1
Methyl Methanesulfonate	increases expression	1
Nickel	decreases expression	1
Tretinoin	decreases expression	1
Valproic Acid	affects expression	1
Aflatoxin B1	increases methylation	1
Copper Sulfate	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer